ALT - NASDAQ

Altimmune, Inc.

ALT·NASDAQ

$2.90

-1.0%

HealthcareBiotechnology

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$255.95M

EPS-1.0000

P/E Ratio-3.61

Earnings Date08/06/2026

alt

Cash and Short Term Investments

Last Annual Value

273.46M

3-Year CAGR

14%

5-Year CAGR

10-Year CAGR

33%

Adjust for Inflation

Altimmune, Inc. Competitors Analysis of Cash and Short Term Investments

ALT · NASDAQ

Company	Cash and Short Term Investments	CAGR 3Y	CAGR 5Y	CAGR 10Y
Altimmune, Inc. NASDAQ:ALT	273.46M	11.4%	7.5%	2.2%
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM	262.90M	28.1%	30.7%	N/A
DiaMedica Therapeutics Inc. NASDAQ:DMAC	59.89M	4.2%	5.8%	42.5%
Humacyte, Inc. NASDAQ:HUMA	50.50M	-14.4%	-25.9%	N/A
Replimune Group, Inc. NASDAQ:REPL	483.80M	-6.0%	0.3%	N/A
Tenaya Therapeutics, Inc. NASDAQ:TNYA	100.55M	-1.3%	-16.7%	N/A
Annexon, Inc. NASDAQ:ANNX	238.34M	-2.8%	-0.4%	N/A
Korro Bio, Inc. NASDAQ:KRRO	75.16M	-23.2%	-10.5%	N/A
LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX	295.21M	89.6%	N/A	N/A
Alto Neuroscience, Inc. NYSE:ANRO	176.48M	28.8%	47.0%	N/A
Aura Biosciences, Inc. NASDAQ:AURA	144.24M	-13.9%	-0.7%	N/A

Altimmune, Inc. Fair Value Envelope

ALT · NASDAQ

Our analysis suggests that ALT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.9, this represents a potential HIDDEN relative to our calculated worth for Altimmune, Inc..

HIDDEN

Intrinsic Value

Current Price: $2.9

Related Guides

Blog Categories

Continue your ALT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.